New Alzheimer’s Drug Slows Cognitive Decline by 35%
Eli Lilly’s donanemab delivers promising Phase 3 data, raising hopes for earlier intervention therapies.
A major Alzheimer’s study released this week confirmed that donanemab, Eli Lilly’s monoclon...